Pharma Braces For Potential Landmark Moment For US Drug Price Controls
Executive Summary
US drug pricing legislation that has picked up momentum could stymie R&D investment and curb the revenue tail for some big drugs, industry says, but CEOs also expect they can navigate the challenge.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.
Gilead Oncology Sales Take Off As Veklury’s Come Down To Earth
As expected, the COVID-19 drug’s sales fell significantly, though it remains in frequent use among hospitalized patients. Meanwhile, oncology drug sales broke the half billion-dollar mark.
AbbVie’s Gonzalez Sounds Alarm On US Drug Price Negotiation Proposal
AbbVie posts solid quarter on strength of Skyrizi growth and continued US growth for Humira ahead of patent expiry. Imbruvica revenue continues to decline, however.